Objective To explore medical equipment management to decrease medical risks.Methods A medical equipment risk management model was established to deploy medical equipment rationally,evaluate the risk value of medical equipment,calculate the total risk value of medical equipment of the department and to propose the requirements for medical equipment utilization and management.Results The risks of medical equipment could be decreased by improved medical equipment management in deployment,utilization and maintenance as well as emphases on personnel and regulation.Conclusion Risk minimization is of great significance for medical equipment users and management department.

Objective To explore the preventive effect of the supplemental dietary boron on bone damage of rats with excess fluoride (EF) ingestion. Methods Twenty-four Sprague-Dawley rats aged 4-5 weeks old were divided into the control (C group, treated with distilled water and the elementary dietary), the excessive fluoride dose group (EF group, treated with distilled water with 100mg/L F-from 221.0g NaF per liter and the elementary dietary) and the boron prevention group (P group, treated with 100mg/L F-distilled water and the supplemental boron dietary). Three months after the experiment, fluorine, boron contents and AKP activities in serum, total RNA and fluorine contents in bone, vertical and transverse diameter and dry weight of tibias of rats were assayed, and bone biomechanics of femur and bone mineral density (BMD) were determined. Results Compared with those in the C group, fluorine contents in serum and bone, AKP activities in serum of rats in the EF group significantly increased; total RNA in bone and BMD of the bone of whole body and tibia decreased, vertical and transverse diameter of tibias was shortened, dry weight was decreased; peak load of femur increased but maximum deformation decreased. Compared with those in EF group, fluorine contents in serum and bone, AKP activities in serum of rats in the P group obviously decreased; total RNA in bone and BMD of whole body, lumbar vertebrae and tibias notably increased, vertical and transverse diameters and dry weight of tibia were enhanced, peak load of femur was obviously raised. Boron contents in serums of rats in three groups had no significant differences. Conclusion Bone damage obviously occurred in rats with EF intake, and the supplemental dietary boron had a preventive effect on these changes.

Objective To investigate the clinical effect of angioplasty for symptomatic intracranial atherosclerotic stenosis. Methods Eighty-two patients with symptomatic intracranial atherosclerotic stenosis whom underwent angioplasty after the failure of standard medical therapy were enrolled from Nan-jing Stroke Registry Program from September 2010 to June 2013.Nine of them underwent routine balloon angioplasty alone and 73 underwent intracranial stenting.The median time from onset to surgery was 24.5 days.The occurrence of endpoint events (any stroke ≤30 d after procedure,death and ischemic stroke >30 d in guilty vessels or original stenosis had restenosis and needed to be treated again)was assessed. The incidence of restenosis was followed up with imaging (CTA or DSA). Results (1)In the 82 patients, the success rate of operation was 92.7%(n=72 ),and 78 (95.1%)received follow-up,4 were lost to follow-up.The median follow-up time was 22.5 months (range 9 to 29 months ).Ten patients had an endpoint event,7 of them were ischemic stroke,1 was cerebral hemorrhage,and two were severe asymptomatic restenosis who underwent stenting again.The endpoint events of 3 patients occurred at day 30 after procedure (at ≤24 h after procedure).Kaplan-Meier curves showed that the incidences of cumulative endpoint events at 1,6,12,and 24 months were 3.7%,8.6%,11%,and 13%,respectively.(2)60 patients (73.2%)received imaging examination (11 CTA and 49 DSA ).Restenosis occurred in 17 patients (28.3%),among them the incidence of symptomatic restenosis was 5%(n =3 ),and asymptomatic restenosis was 23.3%(n=14). Conclusion After a comprehensive assessment and a rigorous screening, the safety is high and the mid- and long-term efficacy are satisfactory in patients with symptomatic intracranial arterial stenosis who are treated with angioplasty when their medical treatment is invalid.

OBJECTIVETo observe clinical efficacy of intra-articular injection of Sodium hyaluronate (SH) accompanied with external application of Sanhua ointment (SHO) for knee osteoarthritis.

METHODSOne hundred and twelve patients with osteoarthritis were randomly divided into two groups, Group I was treated with SH and Group II was treated with SH plus SHO. The entire condition of knee joint in the two groups were compared before and after treatment according to Lysholm's function scoring.

RESULTSThe functional score in the two groups at the 2nd week, 5th week, 3rd month and end of 1st year of the treatment course were significantly higher than that before treatment (P < 0.05), and the scores continuously increased within the first 3 months of treatment. Comparison of scores between the two groups showed that scores in Group II was significantly higher than those in Group I at the corresponding period. The total effective rate after 1 year treatment in Group lI was higher than that in Group II (81.5% vs 96.6%, P < 0.05). In Group II , the initial time of symptom improving was earlier and the adverse effect disappeared more quickly than those in Group I markedly.

CONCLUSIONThe efficacy of combined therapy of intra-articular injection of SH and SHO for knee osteoarthritis was superior to that of intra-articular injection of SH only.

Administration, Topical ; Adult ; Aged ; Drug Therapy, Combination ; Drugs, Chinese Herbal ; administration & dosage ; Female ; Humans ; Hyaluronic Acid ; administration & dosage ; Injections, Intra-Articular ; Male ; Middle Aged ; Osteoarthritis, Knee ; drug therapy ; Phytotherapy

OBJECTIVE: To explore the molecular basis for an A subtype of the ABO blood group. METHODS: The forward and reverse typing of the ABO blood group were identified by gel card and test tube methods. The ABO gene of the patient was detected by PCR-sequence specific primer (PCR-SSP). Exons 1 to 7 of the ABO gene was amplified by PCR and sequenced. The ABO gene was also subjected to subclone sequencing for haplotype analysis. RESULTS: The patient's red cells showed weak agglutination with anti-A but non-agglutination with anti-B. The patient's serum showed 1+ agglutination with A cells and 4+ agglutination with B cells. Based on above serological characteristics, the patient was defined as Aw subtype of the ABO blood group. Sequencing analysis showed that the patient was heterozygous for c.106G>T, c.188G>A, c.189C>T, c.220C>T, c.297A>G, c.467C>T, c.543G>C, c.646T>A, c.681G>A, c.771C>T, c.829G>A, in addition with a c.261G deletion. Combined with the result of subclone sequencing, the ABO genotype of the patient was determined as ABO*AW.33. new/O.01.02, which harbored c.467C>T and c.543G>C variants compared with ABO*A1.01 and c.543G>C variant compared with ABO*A1.02. The novel allele has been submitted to GenBank with an accession number of MK302122. CONCLUSION A novel allele of Aw33 subtype has been identified with its GTA transferase gene harboring c.467C>T and c.543G>C variants compared with A1.01.
ABO Blood-Group System ; genetics ; Alleles ; Exons ; genetics ; Genotype ; Humans ; Phenotype